Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma

Yasuhiro Nakashima, Motoaki Shiratsuchi, Yasunobu Abe, Koichiro Muta, Kenzaburo Tani, Satoshi Shiokawa, Junji Nishimura

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Multiple myeloma (MM) is refractory to conventional chemotherapy. To achieve a sustained complete remission, we performed planned non-myeloablative allogeneic stem cell transplantation (NSTD after autologous hematopoietic stem cell transplantation (HSCT) in a patient with stage III MM. Autologous HSCT was performed using high-dose melphalan after conventional chemotherapy, followed by NST from an HLA-identical sibling using low-dose total body irradiation (200 cGy) for conditioning. Cyclosporine and mycophenolate mofetil were used for graft-vs-host disease (GVHD) prophylaxis. Acute GVHD was transiently seen in the skin and intestine, while, in addition, mild chronic GVHD was seen in the oral mucosa and skin. Complete donor chimerism was achieved and the disappearance of tumor-derived monoclonal B cells was confirmed based on an analysis of immunoglobulin light chain messenger signals on day 156 when chronic GVHD occurred. The clinical course in this case strongly suggested the existence of a graft-vs-myeloma effect.

Original languageEnglish
Pages (from-to)1217-1222
Number of pages6
JournalLeukemia and Lymphoma
Volume46
Issue number8
DOIs
Publication statusPublished - Aug 1 2005

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Graft vs Host Disease
Multiple Myeloma
Mycophenolic Acid
Immunoglobulin Light Chains
Drug Therapy
Skin
Chimerism
Melphalan
Whole-Body Irradiation
Mouth Mucosa
Cyclosporine
Intestines
Siblings
B-Lymphocytes
Tissue Donors
Transplants
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma. / Nakashima, Yasuhiro; Shiratsuchi, Motoaki; Abe, Yasunobu; Muta, Koichiro; Tani, Kenzaburo; Shiokawa, Satoshi; Nishimura, Junji.

In: Leukemia and Lymphoma, Vol. 46, No. 8, 01.08.2005, p. 1217-1222.

Research output: Contribution to journalArticle

@article{e39f19f5cb9c42f9bb66c4030dedbd69,
title = "Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma",
abstract = "Multiple myeloma (MM) is refractory to conventional chemotherapy. To achieve a sustained complete remission, we performed planned non-myeloablative allogeneic stem cell transplantation (NSTD after autologous hematopoietic stem cell transplantation (HSCT) in a patient with stage III MM. Autologous HSCT was performed using high-dose melphalan after conventional chemotherapy, followed by NST from an HLA-identical sibling using low-dose total body irradiation (200 cGy) for conditioning. Cyclosporine and mycophenolate mofetil were used for graft-vs-host disease (GVHD) prophylaxis. Acute GVHD was transiently seen in the skin and intestine, while, in addition, mild chronic GVHD was seen in the oral mucosa and skin. Complete donor chimerism was achieved and the disappearance of tumor-derived monoclonal B cells was confirmed based on an analysis of immunoglobulin light chain messenger signals on day 156 when chronic GVHD occurred. The clinical course in this case strongly suggested the existence of a graft-vs-myeloma effect.",
author = "Yasuhiro Nakashima and Motoaki Shiratsuchi and Yasunobu Abe and Koichiro Muta and Kenzaburo Tani and Satoshi Shiokawa and Junji Nishimura",
year = "2005",
month = "8",
day = "1",
doi = "10.1080/10428190500096708",
language = "English",
volume = "46",
pages = "1217--1222",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Sustained molecular remission by non-myeloablative stem cell transplantation after autologous hematopoietic stem cell transplantation in a patient with multiple myeloma

AU - Nakashima, Yasuhiro

AU - Shiratsuchi, Motoaki

AU - Abe, Yasunobu

AU - Muta, Koichiro

AU - Tani, Kenzaburo

AU - Shiokawa, Satoshi

AU - Nishimura, Junji

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Multiple myeloma (MM) is refractory to conventional chemotherapy. To achieve a sustained complete remission, we performed planned non-myeloablative allogeneic stem cell transplantation (NSTD after autologous hematopoietic stem cell transplantation (HSCT) in a patient with stage III MM. Autologous HSCT was performed using high-dose melphalan after conventional chemotherapy, followed by NST from an HLA-identical sibling using low-dose total body irradiation (200 cGy) for conditioning. Cyclosporine and mycophenolate mofetil were used for graft-vs-host disease (GVHD) prophylaxis. Acute GVHD was transiently seen in the skin and intestine, while, in addition, mild chronic GVHD was seen in the oral mucosa and skin. Complete donor chimerism was achieved and the disappearance of tumor-derived monoclonal B cells was confirmed based on an analysis of immunoglobulin light chain messenger signals on day 156 when chronic GVHD occurred. The clinical course in this case strongly suggested the existence of a graft-vs-myeloma effect.

AB - Multiple myeloma (MM) is refractory to conventional chemotherapy. To achieve a sustained complete remission, we performed planned non-myeloablative allogeneic stem cell transplantation (NSTD after autologous hematopoietic stem cell transplantation (HSCT) in a patient with stage III MM. Autologous HSCT was performed using high-dose melphalan after conventional chemotherapy, followed by NST from an HLA-identical sibling using low-dose total body irradiation (200 cGy) for conditioning. Cyclosporine and mycophenolate mofetil were used for graft-vs-host disease (GVHD) prophylaxis. Acute GVHD was transiently seen in the skin and intestine, while, in addition, mild chronic GVHD was seen in the oral mucosa and skin. Complete donor chimerism was achieved and the disappearance of tumor-derived monoclonal B cells was confirmed based on an analysis of immunoglobulin light chain messenger signals on day 156 when chronic GVHD occurred. The clinical course in this case strongly suggested the existence of a graft-vs-myeloma effect.

UR - http://www.scopus.com/inward/record.url?scp=23144463943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23144463943&partnerID=8YFLogxK

U2 - 10.1080/10428190500096708

DO - 10.1080/10428190500096708

M3 - Article

C2 - 16085565

AN - SCOPUS:23144463943

VL - 46

SP - 1217

EP - 1222

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -